Most Read Articles
Dr. Joseph Delano Fule Robles, 12 Feb 2019

A team of investigators from the University of Hong Kong (HKU) identified high-risk Epstein Barr virus (EBV) variants present in 97 percent of nasopharyngeal carcinoma (NPC) cases.

4 days ago
New drug applications approved by US FDA as of 01- 15 February 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Pearl Toh, 23 Aug 2018
Restoration of CD4/CD8 ratio on combination antiretroviral therapy (cART) was associated with decreased risk of Kaposi sarcoma (KS) while baseline CD8 count was related to non-Hogkin lymphoma (NHL) risk in people living with HIV (PLHIV) who had achieved viral suppression on cART, according to the COHERE* study presented at the AIDS International Conference (AIC) 2018.
Roshini Claire Anthony, 16 Jan 2019

A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.

No link between H. pylori infection and carotid intima-media thickness

09 Oct 2018

There appears to be no meaningful link between Helicobacter pylori infection and carotid intima-media thickness (CIMT) in the general population, according to a recent China study.

Researchers enrolled 13,770 individuals who had undergone both the H. pylori test and CIMT measurements. A minority of the study population tested positive for the infection (39.3 percent; n=5,418; mean age 52.0±12.1 years; 62.5 percent male) while most (n=9,741) did not have increased CIMT.

In those who were positive for the infection, 28.6 percent (n=1,549) showed increased CIMT. This was not significantly different than in those who were negative for the infection (n=8,352; mean age 52.8±12.8 years; 58.5 percent male), of whom 29.7 percent (n=2,480) had increased CIMT (p=0.164).

Conversely, there was no significant difference in the rate of H. pylori infection among those with and without increased CIMT (38.4 percent vs 39.7 percent; p=0.164).

This was further confirmed in binary logistic regression analysis, which showed no significant relationship between CIMT and H. pylori infection status even after adjustments for covariates such as waistline, total cholesterol, blood pressure, fasting plasma glucose and body mass index, among other (odds ratio [OR], 1.118; 95 percent CI, 0.958–1.306; p=0.157).

While the present findings suggest that H. pylori infections are unrelated to CIMT, future, larger studies involving other strains are needed to determine the involvement of the bacteria in atherosclerosis, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 12 Feb 2019

A team of investigators from the University of Hong Kong (HKU) identified high-risk Epstein Barr virus (EBV) variants present in 97 percent of nasopharyngeal carcinoma (NPC) cases.

4 days ago
New drug applications approved by US FDA as of 01- 15 February 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Pearl Toh, 23 Aug 2018
Restoration of CD4/CD8 ratio on combination antiretroviral therapy (cART) was associated with decreased risk of Kaposi sarcoma (KS) while baseline CD8 count was related to non-Hogkin lymphoma (NHL) risk in people living with HIV (PLHIV) who had achieved viral suppression on cART, according to the COHERE* study presented at the AIDS International Conference (AIC) 2018.
Roshini Claire Anthony, 16 Jan 2019

A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.